Supplement encyclopedia

Bifidobacterium bifidum

Bifidobacterium bifidum is a species of bifidobacteria found in some supplements and specially fortified dairy products. Products differ by strain and cell viability. Live MIMBb75 and heat-inactivated HI-MIMBb75 are distinct forms.

Double-check the conclusions and review the sources before choosing a supplement.

Main conclusion

Potential benefits

  • Live MIMBb75 may relieve irritable bowel syndrome symptoms in adults. After four weeks, 43% of participants reported adequate relief versus 8% with placebo.
  • Inactivated HI-MIMBb75 may reduce pain together with overall relief of IBS symptoms in adults. In 74 of 221 participants versus 43 of 222 with placebo, pain decreased by at least 30% and overall symptoms were adequately relieved in at least four of eight weeks.
  • Fermented milk with YIT 10347 and S. thermophilus may relieve temporary digestive complaints in adults: over four weeks, the total symptom score decreased in more participants than in the control group. No convincing difference in the mean complaint score or bloating was found.
  • In adults with lactose intolerance, one month of ice cream containing 900791 showed no convincing advantage in lactose tolerance over control.

[1] [2] [3] [4]

What was studied

  • In students under academic stress, the proportion of days with low-severity cold-like symptoms was higher with R0071 taken for six weeks than with placebo.
  • In adults with constipation, G9-1 showed no convincing advantage in the overall constipation-related quality-of-life score over eight weeks.
  • For immunodeficiency, the Canadian monograph advises avoiding live probiotics. With severe illness, discuss their use with the treating doctor because of infection risk.

[1] [2] [3] [4]

Which forms were studied

  • In separate IBS trials, live MIMBb75 was taken at 1 billion CFU daily for four weeks; heat-inactivated HI-MIMBb75 at 1 billion cells daily for eight weeks. CFU denotes viable bacteria.
  • The student study used R0071 at 3 billion CFU daily for six weeks. On the label, look for the full strain code, CFU count at the end of shelf life, and storage conditions.
  • YIT 10347 was studied in fermented milk, and 900791 in experimental ice cream. With milk protein allergy, check the product’s composition.

[1] [2] [3] [4] [5] [6] [7]

How to get it from food

  • The milk drink studied contained more than 3 billion CFU of YIT 10347 per 100 mL together with S. thermophilus YIT2021 culture. When choosing such a product, check for this exact composition.
  • Strain 900791 was studied at two concentrations in the experimental ice cream. Check the label for the strain’s presence and amount in a particular product.

[1] [2] [3]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Relief of overall digestive symptoms — YIT 10347In the per-protocol analysis, the overall score decreased in 35 of 39 participants receiving YIT 10347 and 28 of 40 controls. The distribution across three categories (improved, unchanged, worsened) differed between groups (p=0.016).
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.
11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups.
  1. Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
Mean overall digestive symptom score — YIT 10347The mean Gastrointestinal Symptom Rating Scale (GSRS) score changed by −0.67 versus −0.46 points (p=0.361). No statistically significant difference was shown.
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.
11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups.
  1. Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
Bloating — YIT 10347Mean bloating scores decreased by 0.62 and 0.70 points, respectively. No significant difference was found between groups (p=0.984).
2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The stated scope is this specific fermented milk product and the outcome measured. The risk-of-bias section accounts for the outcome's secondary status and participant attrition. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Substantial attrition and a narrow comparison involving a specific product limit interpretation.
11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups.
  1. Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Forms

Live MIMBb75 and inactivated HI-MIMBb75: The trial of live MIMBb75 used 1 billion CFU/day for four weeks. The HI-MIMBb75 trial used 1 billion nonviable cells per day for eight weeks. That cell count is not equivalent to the same number of viable CFU. Live R0071, G9-1, and CCFM16: These are distinct strains and preparations. R0071 was studied at 3 billion CFU/day for six weeks, while G9-1 was studied using a specific tablet regimen. Evidence on the dose and form of one strain cannot substitute for evidence on another. YIT 10347 and 900791 in foods: Participants received YIT 10347 in fermented milk that also contained S. thermophilus. Strain 900791 was added to ice cream. Participants received YIT 10347 in fermented milk that also contained S. thermophilus. Strain 900791 was added to ice cream. Do not assume that a capsule can replace either of these food carriers.

Guidance for each goal

Relief of overall digestive symptoms — YIT 103472/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.

In the per-protocol analysis, the overall score decreased in 35 of 39 participants receiving YIT 10347 and 28 of 40 controls. The distribution across three categories (improved, unchanged, worsened) differed between groups (p=0.016).

Study findings. In the per-protocol analysis, the overall score decreased in 35 of 39 participants receiving YIT 10347 and 28 of 40 controls. The distribution across three categories (improved, unchanged, worsened) differed between groups (p=0.016).

Studied regimen100 mL/day, with more than 3×10⁷ CFU/mLB. bifidum YIT 10347 in fermented milk
Duration and population4 weeks100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups.

Comparator: Control fermented milk with S. thermophilus

Mean overall digestive symptom score — YIT 103472/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.

The mean Gastrointestinal Symptom Rating Scale (GSRS) score changed by −0.67 versus −0.46 points (p=0.361). No statistically significant difference was shown.

Study findings. The mean Gastrointestinal Symptom Rating Scale (GSRS) score changed by −0.67 versus −0.46 points (p=0.361). No statistically significant difference was shown.

Studied regimen100 mL/day, with more than 3×10⁷ CFU/mLB. bifidum YIT 10347 in fermented milk
Duration and population4 weeks100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups.

Comparator: Control fermented milk with S. thermophilus

Bloating — YIT 103472/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The stated scope is this specific fermented milk product and the outcome measured. The risk-of-bias section accounts for the outcome's secondary status and participant attrition. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Substantial attrition and a narrow comparison involving a specific product limit interpretation.

Mean bloating scores decreased by 0.62 and 0.70 points, respectively. No significant difference was found between groups (p=0.984).

Study findings. Mean bloating scores decreased by 0.62 and 0.70 points, respectively. No significant difference was found between groups (p=0.984).

Studied regimen100 mL/day, with more than 3×10⁷ CFU/mLB. bifidum YIT 10347 in fermented milk
Duration and population4 weeks100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups.

Comparator: Control fermented milk with S. thermophilus

Overall IBS symptom relief — live MIMBb752/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.

By the end of 4 weeks, 43% of participants receiving live MIMBb75 and 8% receiving placebo reported adequate relief. At 2 weeks after treatment ended, the figures were 47% and 11%, respectively.

Study findings. By the end of 4 weeks, 43% of participants receiving live MIMBb75 and 8% receiving placebo reported adequate relief. At 2 weeks after treatment ended, the figures were 47% and 11%, respectively.

Studied regimen1 capsule daily, providing 1 billion CFU/dayLive B. bifidum MIMBb75
Duration and population4 weeks122 adults with IBS: 60 in the strain group and 62 in the placebo group

Comparator: Placebo

Pain reduction with overall IBS symptom relief — HI-MIMBb752/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.

Among participants receiving HI-MIMBb75, 74 of 221 met both criteria in at least 4 of the 8 weeks, as did 43 of 222 receiving placebo. The criteria were a reduction of at least 30% in abdominal pain and adequate relief of overall symptoms. The relative likelihood of this response was 1.7 (95% confidence interval 1.3–2.4).

Study findings. Among participants receiving HI-MIMBb75, 74 of 221 met both criteria in at least 4 of the 8 weeks, as did 43 of 222 receiving placebo. The criteria were a reduction of at least 30% in abdominal pain and adequate relief of overall symptoms. The relative likelihood of this response was 1.7 (95% confidence interval 1.3–2.4).

Studied regimenTwo capsules taken together once daily, providing a total of 1 billion inactivated cells per dayHeat-inactivated B. bifidum HI-MIMBb75
Duration and population8 weeks443 adults with IBS: 221 in the strain group and 222 in the placebo group

Comparator: Placebo

Quality of life with constipation — G9-12/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.

The overall constipation-related quality-of-life score changed by −0.65 versus −0.54 points. No significant advantage over the comparator was found.

Study findings. The overall constipation-related quality-of-life score changed by −0.65 versus −0.54 points. No significant advantage over the comparator was found.

Studied regimenTwo study tablets three times dailyB. bifidum G9-1 tablets
Duration and population8 weeks150 adults with constipation were randomized, and 140 were included in the analysis. Participants could continue stable usual care.

Comparator: Placebo alongside usual care

Stool outcomes in chronic constipation — CCFM162/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: Direct evidence for the specified participants, strain, form, and outcome. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: This was a small study of a subjective outcome. Details on the analysis or group allocation were incomplete, and multiple comparisons were made.

One study reported improved stool consistency and a higher proportion of stool responders, but overall symptoms and quality of life did not differ significantly.

Study findings. One study reported improved stool consistency and a higher proportion of stool responders, but overall symptoms and quality of life did not differ significantly.

Studied regimenAccording to tables in two reviews, 2 billion CFU once daily.B. bifidum CCFM16 powder, according to the review table
Duration and population28 days103 adults with chronic constipation

Comparator: Placebo

Lactose tolerance after one month of use — 9007911/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: Direct evidence for the specified adults with lactose intolerance and this product. The risk-of-bias section accounts for attrition and the lack of dietary control. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: The final test was missing for one third of participants. Blinding and the order of interventions were unclear. The result depends on the specific food used as the carrier.

After one month of use, no benefit over the control was found. Only 29 of 45 participants completed the final test, making the estimate imprecise.

Study findings. After one month of use, no benefit over the control was found. Only 29 of 45 participants completed the final test, making the estimate imprecise.

Studied regimen50 g of ice cream per day at 10⁵ CFU/g, equivalent to 5 million CFU/dayLive B. bifidum 900791 in ice cream
Duration and population4 weeks45 adults with a positive hydrogen breath test and symptoms were randomized. Of these, 29 completed the final test.

Comparator: The same ice cream without the study strain

Days with low severity of cold-like symptoms — R00712/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below.

Students receiving R0071 recorded a higher proportion of days with a total score of 6 or less across nine symptoms. A total score above 6 was recorded on 118 observation days with R0071 and 222 days with placebo.

Study findings. Students receiving R0071 recorded a higher proportion of days with a total score of 6 or less across nine symptoms. A total score above 6 was recorded on 118 observation days with R0071 and 222 days with placebo.

Studied regimen3 billion CFU/dayB. bifidum R0071
Duration and population6 weeksIn a setting of academic stress, 583 students were randomized to four groups, and 581 were included in the analysis.

Comparator: Placebo

Mental well-being and quality of life — YIT 103472/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The stated scope is this specific fermented milk product and the outcome measured. The risk-of-bias section accounts for the outcome's secondary status and participant attrition. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Substantial attrition and a narrow comparison involving a specific product limit interpretation.

Secondary measures of mental well-being and quality of life did not differ significantly between groups. This was not a standalone trial of sleep disorders.

Study findings. Secondary measures of mental well-being and quality of life did not differ significantly between groups. This was not a standalone trial of sleep disorders.

Studied regimen100 mL per day, with more than 3×10⁷ CFU/mLB. bifidum YIT 10347 in fermented milk
Duration and population4 weeks100 adults with transient digestive symptoms, with 79 included in the per-protocol analysis

Comparator: Control fermented milk with S. thermophilus

Safety and limitations

Gas and temporary digestive discomfort are possible. In the R0071 trial, one participant stopped taking it because of diarrhea. A single case cannot establish how often diarrhea occurs across products. At week 4 of a small study, acidic stomach contents coming back up (acid regurgitation) was reported more often in the group receiving ice cream containing B. bifidum 900791 than in the control group (p < 0.01). Rare infections linked to live probiotics have been reported mainly in vulnerable people. A Canadian monograph advises people with immunodeficiency to avoid live probiotics. For people with serious illness and for preterm infants, use should be discussed with the treating physician. The FDA warning concerned a different bacterial species, B. longum. Small studies in pregnant women and full-term infants do not establish the safety of all strains or of long-term use. If you have a milk protein allergy, check the ingredients of any dairy carrier.

Probiotics — Health Professional Fact Sheet (NIH ODS) ↗ · Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study ↗ · Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗ · Improvement in Lactose Tolerance in Hypolactasic Subjects Consuming Ice Creams with High or Low Concentrations of Bifidobacterium bifidum 900791 ↗ · Probiotics — Health Canada Natural Health Product Monograph ↗

Interactions

WithEffectActionSource
Antibiotics and live probioticsThis guidance comes from the Canadian monograph for live bacterial probiotics. The monograph does not cover heat-inactivated preparations.Take a live probiotic at least 2–3 hours before or after an antibiotic. Check the instructions for both products.Probiotics — Health Canada Natural Health Product Monograph ↗

Food sources

Food composition

FoodGroupAmountServingCaloriesSources
Fermented milk with YIT10347Studied formulation with S. thermophilus YIT2021Fermented dairy drinks—In the trial, participants drank 100 mL daily, providing more than 3 billion CFU of YIT10347 per serving. This was a specific formulation. Ordinary milk or yogurt does not necessarily have the same composition.——Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
Ice cream with B. bifidum 900791Experimental fortified ice creamFrozen dairy products—The study used two concentrations of 900791: 10⁵ and 10⁷ CFU/g. The strain was confirmed in these samples. This finding does not apply to ordinary ice cream, and the samples are not equivalent to R0071 capsules.——Improvement in Lactose Tolerance in Hypolactasic Subjects Consuming Ice Creams with High or Low Concentrations of Bifidobacterium bifidum 900791 ↗

Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗Relief of overall digestive symptoms — YIT 10347: Relief of overall digestive symptoms — YIT 10347 Mean overall digestive symptom score — YIT 10347: Mean overall digestive symptom score — YIT 10347 Bloating — YIT 10347: Bloating — YIT 10347 Mental well-being and quality of life — YIT 10347: Mental well-being and quality of life — YIT 10347Relief of overall digestive symptoms — YIT 10347: 100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups. Mean overall digestive symptom score — YIT 10347: 100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups. Bloating — YIT 10347: 100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups. Mental well-being and quality of life — YIT 10347: 100 adults with transient digestive symptoms, with 79 included in the per-protocol analysisRelief of overall digestive symptoms — YIT 10347: B. bifidum YIT 10347 in fermented milk, 100 mL/day with more than 3×10⁷ CFU/mL for 4 weeks. Comparator: control fermented milk with S. thermophilus. Mean overall digestive symptom score — YIT 10347: B. bifidum YIT 10347 in fermented milk, 100 mL/day with more than 3×10⁷ CFU/mL for 4 weeks. Comparator: control fermented milk with S. thermophilus. Bloating — YIT 10347: B. bifidum YIT 10347 in fermented milk, 100 mL/day with more than 3×10⁷ CFU/mL for 4 weeks. Comparator: control fermented milk with S. thermophilus. Mental well-being and quality of life — YIT 10347: B. bifidum YIT 10347 in fermented milk, 100 mL per day with more than 3×10⁷ CFU/mL for 4 weeks. Comparator: control fermented milk with S. thermophilus.Relief of overall digestive symptoms — YIT 10347: In the per-protocol analysis, the overall score decreased in 35 of 39 participants receiving YIT 10347 and 28 of 40 controls. The distribution across three categories (improved, unchanged, worsened) differed between groups (p=0.016). Mean overall digestive symptom score — YIT 10347: The mean Gastrointestinal Symptom Rating Scale (GSRS) score changed by −0.67 versus −0.46 points (p=0.361). No statistically significant difference was shown. Bloating — YIT 10347: Mean bloating scores decreased by 0.62 and 0.70 points, respectively. No significant difference was found between groups (p=0.984). Mental well-being and quality of life — YIT 10347: Secondary measures of mental well-being and quality of life did not differ significantly between groups. This was not a standalone trial of sleep disorders.
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study ↗Overall IBS symptom relief — live MIMBb75122 adults with IBS: 60 in the strain group and 62 in the placebo groupLive B. bifidum MIMBb75, 1 capsule daily providing 1 billion CFU/day for 4 weeks. Comparator: placebo.By the end of 4 weeks, 43% of participants receiving live MIMBb75 and 8% receiving placebo reported adequate relief. At 2 weeks after treatment ended, the figures were 47% and 11%, respectively.

Sources

Sources
  1. Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
  2. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study ↗
  3. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial ↗
  4. Bifidobacterium bifidum G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-Blind, Randomized Controlled Trial ↗
  5. A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of the gut microbiota and relief from chronic constipation ↗
  6. Improvement in Lactose Tolerance in Hypolactasic Subjects Consuming Ice Creams with High or Low Concentrations of Bifidobacterium bifidum 900791 ↗
  7. Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study ↗
  8. Probiotics — Health Professional Fact Sheet (NIH ODS) ↗
  9. Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗
  10. Crosstalk between the Gut Microbiome and Colonic Motility in Chronic Constipation: Potential Mechanisms and Microbiota Modulation ↗
  11. Targeting Gut Microbiota in the Management of Functional Constipation: A Narrative Review ↗
  12. Constipation targeted monostrain and multispecies probiotics: effects on symptoms and gut microbiota ↗
  13. Probiotics — Health Canada Natural Health Product Monograph ↗